BSX — Boston Scientific Cashflow Statement
0.000.00%
- $150.72bn
- $161.28bn
- $16.75bn
- 92
- 13
- 98
- 76
Annual cashflow statement for Boston Scientific, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -82 | 1,041 | 698 | 1,592 | 1,846 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 508 | 212 | 761 | 487 | 851 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 41 | -351 | -1,006 | -771 | -462 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 1,508 | 1,871 | 1,526 | 2,503 | 3,434 |
Capital Expenditures | -522 | -554 | -588 | -711 | -790 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 111 | -1,043 | -1,423 | -1,863 | -4,897 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Change in Net Intangibles | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -411 | -1,597 | -2,011 | -2,574 | -5,687 |
Financing Cash Flow Items | -206 | -150 | -464 | -145 | -243 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 293 | -95 | -548 | 5 | 1,814 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1,388 | 173 | -1,042 | -70 | -450 |